



# Glucose tolerance status in patients with newly diagnosed papillary thyroid carcinoma

Nasser Aghamohammadzadeh<sup>1</sup>, Taghi Fadayi Haghi<sup>2</sup>, Jalil Houshyar<sup>1</sup>, Farzad Najafipour<sup>1\*</sup>

<sup>1</sup>Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup>Department of Internal Medicine, Tabriz University of Medical Science, Tabriz, Iran

## \*Correspondence to

Farzad Najafipour, Email:  
Farzadnajafipour@gmail.com,  
Najafipourf@tbzmed.ac.ir

Received 10 Sep. 2020

Accepted 19 Nov. 2020

Published online 30 Nov. 2020

**Keywords:** Papillary thyroid cancer, Insulin resistance, Oral glucose tolerance test

## Abstract

**Introduction:** Thyroid cancer is one of the most common endocrine system malignancies with 9 out of 100,000 estimated annual incidence and papillary carcinoma is the most common type of thyroid cancer. Papillary thyroid cancer (PTC) increases blood insulin levels by creating insulin resistance. Many studies have suggested the role of insulin resistance in the prognosis of PTC.

**Objectives:** The aim of the present study was to determine the prevalence of impaired glucose tolerance in patients with PTC and to compare the relationship between insulin resistance and disease severity, lymph node involvement and distant metastasis.

**Patients and Methods:** In this cross-sectional study, 68 patients with PTC diagnosis examined for metastasis by whole body scan and cervical lymph nodes by ultrasound were included in this study. A 75 g oral glucose tolerance test was also performed on subjects.

**Results:** In this study 68 patients (76.5% female and 23.5% male) were enrolled. The mean age of the patients was  $44.2 \pm 13.8$  years. The mean serum level of fasting blood glucose (FBG) in patients was  $103.14 \pm 21.8$  mg/dL and the mean 2 hours post-prandial was  $145.12 \pm 22.37$  mg/dL. Statistically significant lymphatic involvement was observed in 25% of patients between insulin resistance and nodal involvement ( $P=0.03$ ). A significantly higher metastasis was also observed in 16.2% of patients with glucose intolerance ( $P<0.05$ ).

**Conclusion:** The results indicated that the rate of insulin resistance in PTC patients is significantly higher and glucose intolerance in these patients is associated with increased lymphatic involvement and increased risk of metastasis and poor prognosis.

## Citation:

Aghamohammadzadeh N, Fadayi Haghi T, Houshyar J, Najafipour F. Glucose tolerance status in patients with newly diagnosed papillary thyroid carcinoma. Immunopathol Persa. 2024;10(1):e18218. DOI:10.34172/ipp.2022.18218.



## Introduction

Thyroid cancer is the most common malignancy of endocrine system, affecting approximately 9 out of 100 000 people per year (1). Many thyroid cancers initially present as asymptomatic nodules, and papillary thyroid cancer (PTC) is the most common thyroid malignancy, which accounts for about 70 to 90% of thyroid cancers. The average age of diagnosis is 45 years and the onset of the disease occurs in childhood and incidence increases with age (2). PTC originates from epithelial follicular cell which responds to TSH stimulation like normal epithelium tissue (3). In general, cancers cause insulin resistance by multiple mechanisms such as impaired glucose tolerance and diabetes (4). Glucose tolerance test is one of the most effective methods to predict the incidence of diabetes in patients. In some cases blood glucose level between 140 to 200 mg/dL is considered as impaired glucose control two hours after 75 g glucose consumption and the

## Key point

Insulin resistance and impaired glucose tolerance are associated with increased incidence of nodal lymph involvement and metastasis and decreased papillary thyroid cancer prognosis.

patient needs serious control and attention regarding diabetes (5).

PTC is one of the most common cancers causing increased blood insulin level by insulin resistance induction. Insulin as an anabolic hormone stimulates cell growth. Similar properties are also observed regarding the thyroid gland which in turn increases the volume of the cancerous mass, the volume of the thyroid gland, and the number of thyroid nodules. Recent studies suggest that insulin resistance is associated with increased resistance to PTC treatment. In addition, due to the larger mass size of the nodule, patients with insulin resistance have a poor prognosis and the recurrence rate is higher compared

to the other patients (6,7). Several studies suggest the role of insulin resistance in the severity of PTC; however, the higher prevalence of insulin resistance in these patients is debated. The determination of the insulin resistance prevalence and impaired glucose tolerance is a prelude to overt diabetes. In case with higher insulin resistance prevalence, urgent decision making is necessary; because accurate control of blood sugar and improvement of insulin resistance with common treatments can be effective in the prognosis of the underlying disease and additionally reduces the underlying problems which are developed with prolonged diabetes (3,8). Measurement of the fasting blood glucose (FBG) and glucose tolerance test is the simplest method to assess insulin resistance. In this regard, when the blood glucose level is between blood glucose is between 140 to 200 mg/dL, the glucose control is impaired and more severe diabetic control is needed (5).

### Objectives

According to above mentioned information and the need for accurate assessment of glucose metabolism in PTC patients, we decided to determine the prevalence of impaired glucose tolerance in PTC patients, compare blood glucose changing with thyroid mass volume and the likelihood of metastasis.

### Patients and Methods

#### Study design

This cross-sectional study was performed on patients with newly diagnosed PTC referred to Imam Reza hospital at Tabriz University of Medical Sciences from September 2016 to September 2017. The minimum estimated sample size for this study with 95% confidence level and 80% power was 68. Histopathologically confirmed PTC patients which were respectively assessed by whole-body scan and ultrasound regarding the metastasis and cervical lymph nodes status were enrolled in this study. Then, glucose tolerance test was done by using 75 g of oral glucose to assess insulin resistance. Glucose was measured based on enzymatic and colorimetric methods. Glucose is first hydrolyzed by glucose oxidase with gluconic acid and hydrogen peroxide, and then hydrogen peroxidase reacts with 4-hydroxy benzoic acid and 4-aminoantipyrine in the presence of peroxidase to form a red color that concentrates the color intensity with concentration. Available in the sample and the measurable wavelength for glucose is 546 nm. In the present study, blood glucose levels were determined using a Pars Azmoun kit and an autoanalyzer (Alcyon 300).

Inclusion criteria were patients with PTC referring to the endocrine clinic with a pathological diagnosis. History of diabetes, malignancy treatment at the same time or previous history of another malignancy, thyroid gland surgery, pregnancy, and carbohydrate cycle disorders were also considered as exclusion criteria.

FBG, glucose tolerance test, the presence of

distant metastases, existence of nodal involvement (lymphadenopathy), the size of the lymph nodes involved in the presence of lymphadenopathy, and diagnosed variant of carcinoma were then evaluated. Thyroid mass size, metastasis to distant areas and nodal involvement, which play a key role in determining the outcomes of the disease in these patients were also evaluated.

#### Statistical analysis

All data were analyzed using Statistical Package for Social Sciences (SPSS) software 23.0. Chi-square test was used for comparing mean values between two groups.  $P < 0.05$  was also considered as statistically significant.

#### Results

76.5% and 23.5% of patients were female and male, respectively. Mean age of individuals was  $44.24 \pm 13.8$  years. Metastasis was observed in 16.2% with a significantly higher frequency in patients with glucose intolerance ( $P < 0.05$ ). Mean serum level of FBG and 2-hour post-prandial (2hpp) were  $103.21 \pm 14.8$  mg/dL and  $145.12 \pm 22.37$  mg/dL, respectively. The mean tumor size in all subjects was  $24.8 \pm 10.07$  mm. According to the pathological reports, classic type was the most common type of tumor with a frequency of 67.65%. The frequencies of follicular and tall cell variants were also 17.65% and 7.35%, respectively. Other uncommon variants of tumors including columnar, trabecular, hobnail, multifocal and oncocytic, also shared 7.35% of frequency (Table 1).

No significant relationship was found between the tumor variant and patients' gender ( $P = 0.09$ ). Regarding the mean age of patients with each of the PTC variants, a significant relationship was also found between the group with tall cell variant and other groups ( $P = 0.002$ ; Table 2).

Considering the  $GTT > 140$  mg/dL as glucose intolerance, 37 patients (54.4%) had glucose intolerance and were considered as insulin resistant. No significant correlation was found between GTT results between the groups with different PTC variants ( $P > 0.05$ ). The mean tumor size in patients with insulin resistance was also clinically larger than that of non-insulin resistant patients; however, this difference was not statistically significant ( $P = 0.096$ ). The mean dimensions of tumor in two groups with and without insulin resistant were  $26.10 \pm 7.2$  and  $22.6 \pm 9.6$  mm, respectively ( $P = 0.088$ ) (Table 3). Moreover, 25% of patients had lymph node involvement, which was significantly correlated with the presence of insulin resistance ( $P = 0.03$ ).

#### Discussion

Comparison of the present results with global statistics shows that the percentage of insulin resistance is significantly higher in PTC patients. As in our study, insulin resistance was observed in more than 50% of the patients; according to statistics, only about 10-25% of the population is reported to have insulin resistance regarding

**Table 1.** General characteristics of the patients

Parameter	Values
Gender (% female)	76.5
Age (y)	44.24±13.8
Metastasis (%)	16.2
FBG (mg/dL)	103.21±14.8
2hpp	145.12±22.37
Tumor size (mm)	24.8±10.07
Tumor Type, (%)	
Classic type	67.65
Follicular variant	17.65
Tall cell variant	7.35
Other	7.35

Data are presented as mean ± standard deviation (SD) or percent.

**Table 2.** Mean age of patients with each of the PTC variants.

PTC variants	Mean age
Classic type	43.72±13.45
Follicular variant	42.17±8.79
Tall cell variant	64.6±8.23
Other types	33.6±14.7
Total	43.24±13.8

the racial differences (9-13). The results of this study also showed that not only the percentage of insulin resistance in patients with PTC is higher than normal population, but also disease complications and lymph node involvement and distant metastasis have a significant correlation with insulin resistance. Since the prognosis of PTC is directly related to the presence of lymphadenopathy and the presence or absence of distant metastasis and regarding the fact that the patient's survival severely is reduced in the presence of metastasis; therefore, it can be concluded that the existence of insulin resistance is directly correlated with reduced PTC prognosis (14). Pitoia et al(6) showed that insulin resistance is significantly associated with increased PTC resistance to therapy. In addition, patients with insulin resistance had a worse prognosis compared to other patients. Sahin et al (7) also reported a higher insulin resistance rate in PTC patients than that of the average population which was directly correlated with tumor size. Bae et al (15) in a study on 1272 individuals (PTC patients and controls) also reported similar results. However, no association was observed between the presence of insulin resistance and the severity of PTC symptoms and complications which may be due to study on only female population, and different sample size. Paulus et al (3) also found that the prevalence of diabetes in new diagnosed PTC patients is significantly higher.

The results of the above mentioned studies are in line with our results; since all of them suggest the higher

**Table 3.** Tumor size, tumor dimension and lymph node involvement in insulin resistant and non-insulin resistant patients

Parameters	Insulin resistant	Non-insulin resistant	P
Number (%)	35 (54.4)	31 (45.6)	0.6
Tumor size (mm)	26.7±10.2	22.6±9.6	0.096
Tumor dimension (mm)	26.1±7.2	22.6±9.6	0.088
Lymph node involvement (%)	25	75	0.03

Data are presented as mean±standard deviation (SD) or percent.  $P<0.05$  was considered as statistically significant.

insulin resistance rate in PTC patients. Additionally, previous studies have also indicated the association of decreased PTC prognosis and insulin resistance which are in line with our findings. Balkan et al (16) in a study compared 41 patients with thyroid cancer and 41 patients with nodular goiter. Data revealed that despite the effect of insulin resistance on increased thyroid cells growth and increased thyroid nodules prevalence, it does not have a higher prevalence in patients with thyroid cancer.

Bae et al (15) in their study also compared two groups of patients with thyroid tissue defects. Therefore, the different findings in their study may be due to different modeling of their study with the present study.

In a cohort study by Shi et al (17) on different variants of 6282 PTC patients, it has been reported that 74.8%, 17.9%, and 8.3% of patients were classic, follicular and tall cell variants, respectively. Similar results have also been reported by Nath et al (18) study, regarding the different PTC variants prevalence, which are consistent with our findings.

Regarding the size of the primary tumor in PTC patients, different findings have also been reported by studies. Based on these studies, the average size of these tumors varies from 8.2 mm to 40 mm depending on the gender, variant and the presence of co-morbidities (19-22). The average size of the tumor in our study was 24.8 mm.

## Conclusion

The results of the present study indicate that the rate of insulin resistance in PTC patients is significantly higher than the other individuals. Additionally, insulin resistance and impaired glucose tolerance are associated with increased incidence of nodal lymph involvement and metastasis and decreased PTC prognosis.

## Limitations of the study

The major limitation of this study is small sample size due to the rarity of the disease.

## Acknowledgments

This work has been done as part of the Internal Medicine Specialty Dissertation for Taghi Fadayi Haghi. The authors would like to acknowledge Endocrine Research Center and Department of Internal Medicine at Tabriz University of Medical Sciences (Iran) for their great help.

**Authors' contribution**

**Conceptualization:** Nasser Aghamohammadzadeh, Taghi Fadayi Haghi, Farzad Najafipour

**Data curation:** Jalil Houshyar, Nasser Aghamohammadzadeh

**Formal analysis:** All authors.

**Investigation:** Farzad Najafipour.

**Methodology:** Nasser Aghamohammadzadeh.

**Project administration:** Farzad Najafipour.

**Resources:** Nasser Aghamohammadzadeh, Taghi Fadayi Haghi.

**Software:** Nasser Aghamohammadzadeh.

**Supervision:** Farzad Najafipour, Jalil Houshyar, Nasser Aghamohammadzadeh.

**Validation:** Jalil Houshyar, Nasser Aghamohammadzadeh.

**Visualization:** Nasser Aghamohammadzadeh, Farzad Najafipour.

**Writing—original draft:** Jalil Houshyar, Nasser Aghamohammadzadeh.

**Writing—review & editing:** Farzad Najafipour, Jalil Houshyar.

**Conflicts of interest**

The authors declare that they have no competing interests.

**Ethical issues**

The research followed the tenets of the Declaration of Helsinki. The study was approved by the ethics committee of Tabriz University of Medical Sciences (code: IR.GUMS.REC.1398.076). Accordingly, informed consent was obtained from all the patients. This work has been done as part of the internal medicine specialty dissertation by Taghi Fadayi Haghi. Moreover, Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission and redundancy) have been completely observed by the authors.

**Funding/Support**

This study was supported by Endocrine Research Center at Tabriz University of Medical Sciences, Iran (Grant # 62248).

**References**

- Haugen BR. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid CAncer: What is new and what has changed? *Cancer*. 2017;123:372-381. doi: 10.1002/cncr.30360.
- Ho AS, Luu M, Barrios L, Chen I, Melany M, Ali N, et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. *JAMA Oncol*. 2020;6(5):706-713. doi: 10.1001/jamaoncol.2019.6851.
- Paulus YM, Riedel ER, Sabra MM, Tuttle RM, Kalin MF. Prevalence of diabetes mellitus in patients with newly evaluated papillary thyroid cancer. *Thyroid Res*. 2014;7:7. doi: 10.1186/1756-6614-7-7.
- Esposito K, Capuano A, Giugliano D. Metabolic syndrome and cancer: holistic or reductionist? *Endocrine*. 2014;45:362-4. doi: 10.1007/s12020-013-0056-2.
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344:1343-50. doi: 10.1056/NEJM200105033441801.
- Pitoia F, Abelleira E, Bueno F, Urciuoli C, Schmidt A, Niepomniszcze H. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. *Endocrine*. 2015;48:894-901. doi: 10.1007/s12020-014-0416-6.
- Sahin M, Uçan B, Giniş Z, Topaloğlu O, Güngüneş A, Bozkurt NÇ, Arslan MS. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients. *Med Oncol*. 2013;30:589. doi: 10.1007/s12032-013-0589-5.
- Rezzónico JN, Rezzónico M, Pusioli E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. *Metab Syndr Relat Disord*. 2009;7:375-80. doi: 10.1089/met.2008.0062.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28:412-9. doi: 10.1007/BF00280883.
- Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. *N Engl J Med*. 1993;329:1988-92. doi: 10.1056/NEJM199312303292703.
- Ohnishi H, Saitoh S, Ura N, Takagi S, Obara F, Akasaka H, et al. Relationship between insulin resistance and accumulation of coronary risk factors. *Diabetes Obes Metab*. 2002;4:388-93. doi: 10.1046/j.1463-1326.2002.00232.x.
- Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. *Diabetes*. 1998;47:1643-9. doi: 10.2337/diabetes.47.10.1643.
- Do HD, Lohsoonthorn V, Jiamjarasrangsri W, Lertmaharit S, Williams MA. Prevalence of insulin resistance and its relationship with cardiovascular disease risk factors among Thai adults over 35 years old. *Diabetes Res Clin Pract*. 2010;89:303-8. doi: 10.1016/j.diabres.2010.04.013.
- Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. *World J Surg*. 2010;34:1192-202. doi: 10.1007/s00268-009-0364-0.
- Bae MJ, Kim SS, Kim WJ, Yi YS, Jeon YK, Kim BH, et al. High prevalence of papillary thyroid cancer in Korean women with insulin resistance. *Head Neck*. 2016;38:66-71. doi: 10.1002/hed.23848.
- Balkan F, Onal ED, Usluogullari A, Tuzun D, Ozdemir D, Inancli SS, et al. "Is there any association between insulin resistance and thyroid cancer?: A case control study". *Endocrine*. 2014;45:55-60. doi:10.1007/s12020-013-9942-x.
- Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. *J Clin Endocrinol Metab*. 2016;101:264-74. doi: 10.1210/jc.2015-2917.
- Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. *Adv Anat Pathol*. 2018;25:172-9. doi: 10.1097/PAP.0000000000000184.
- Ertek S, Yılmaz NC, Cicero AF, Vurupalmaz Ö, Demiröz AS, Erdoğan G. Increasing diagnosis of thyroid papillary carcinoma follicular variant in south-east Anatolian region: comparison of characteristics of classical papillary and follicular variant thyroid cancers. *Endocr Pathol*. 2012;23(3):157-60. doi: 10.1007/s12022-012-9216-9.
- Abrosimov A, Saenko V, Meirmanov S, Nakashima M, Rogounovitch T, Shkurko O, et al. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression. *Endocr Pathol*. 2007;18:68-75. doi: 10.1007/s12022-007-0012-x.
- Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. *Clin Endocrinol (Oxf)*. 2008;68:618-34. doi: 10.1111/j.1365-2265.2007.03077.x
- Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. *Thyroid*. 2013;23:1423-30. doi: 10.1089/thy.2013.0036.